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to ≥ 3 groups which initiate double-blind active therapy at different times from 
baseline, preceded by 0,1, 2 or more intervals of placebo. Analytical and simulation-
based investigations were conducted to compare the statistical power, required 
assumptions, practical considerations and economic features of the Blind Start to 
conventional single-arm and randomized designs. Results: Given the same num-
ber of patients, the randomized Blind Start provides equivalent statistical power for 
detecting changes pre- vs. post-treatment compared to a conventional single-arm 
design. However, by concealing treatment initiation times, the Blind Start enables 
more objective assessments of outcomes that are effort-based, patient-reported 
or subjectively assessed by investigators. In addition, compared to a conventional 
2-arm randomized trial, analysis of parallel treatment and placebo groups embed-
ded within a Blind Start design provides greater power to detect treatment effects 
over any fixed time interval. For example, with N= 16 and a treatment effect equal 
to 1 standard deviation of the outcome measure, a 4-arm Blind Start design provides 
85% power in a pre-post analysis and 79% power in an analysis of embedded paral-
lel groups. In contrast, a conventional 2-arm randomized trial provides 52% power 
in this scenario. Benefits of the Blind Start design come at the expense of 1) more 
patient-time in the trial and 2) lack of stringent control over patient status upon 
active treatment initiation. ConClusions: The randomized Blind Start design can 
improve precision for treatment effect estimation vs. parallel-group designs and 
reduce risk of bias vs. single-arm designs. Endpoint choice and statistical analysis 
strategies for the Blind Start design can maximize the assessment of treatment 
effects on multiple outcomes.
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objeCtives: The economic evaluation of health care interventions is now an 
accepted element of health care decision-making and priority-setting. As the num-
ber of published economic evaluations has grown, so has the number of systematic 
reviews of economic evaluations. However, the quality of search methodology used in 
recent reviews has not been widely investigated. This study sought to identify which 
search resources are being used to identify studies in recent, published systematic 
reviews of economic evaluations, and to investigate whether choice of resources 
reflects current recommendations for the conduct of such reviews. Methods: 
A search to identify systematic reviews of economic evaluations published since 
January 2013 was undertaken in MEDLINE. Two reviewers extracted the following 
information from reviews which met the inclusion criteria: general medical litera-
ture databases searched, specialist economic databases searched, health technology 
assessment sources searched, supplementary search techniques used. Results were 
compared against the search resources recommended by NICE when searching for 
economic evidence for single technology appraisals, and the summary of current 
best evidence provided in Sure Info (http://vortal.htai.org/?q= node/336). Results: 
Sixty-five systematic reviews met the inclusion criteria; 23 of these could not be 
accessed in full text, data was extracted from 42 reviews. Five reviews (12%) met 
or exceeded the search resources recommended by NICE (MEDLINE, Embase, NHS 
EED, EconLit). Nine reviews (21%) searched at least four of the six types of resource 
recommended by Sure Info (specialist economic databases, general databases, HTA 
databases, webpages of HTA agencies, grey literature, collections of utility studies). 
None of the reviews searched all six. Although all reviews explicitly described the 
resources searched, reporting frequently contained errors or lack of clarity in the 
names of databases and interfaces. ConClusions: The information resources used 
to identify evidence for the majority of recently published systematic reviews of 
economic evaluations do not conform to current recommendations.
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objeCtives: Retrospective database studies rely on the ability to accurately iden-
tify patient cohorts of interest within health care databases. Diagnosis code-based 
algorithms are the primary method of identifying patient cohorts; however, many 
databases lack reliable diagnosis code information. Our aim was to develop precise 
algorithms based on medication claims/prescriber visit (MC/PV) to identify psoriasis 
(PsO) patients or psoriatic patients with arthritic conditions (PsO-AC), a proxy for 
psoriatic arthritis, in databases lacking diagnosis codes. Methods: Algorithms 
were developed using medications with narrow indication profiles in combina-
tion with prescriber specialty to define PsO and PsO-AC. For the study period of 
July 1, 2009 to June 30, 2013, algorithms were validated using the PharMetrics Plus™ 
(PharMetrics) database, which contains both adjudicated medication claims and 
diagnosis codes. Positive predictive value (PPV), negative predictive value (NPV), sen-
sitivity and specificity of algorithms developed for PsO and PsO-AC were assessed 
using diagnosis code as the reference standard. Results: In the PharMetrics data-
base, 183,328 patients were identified by diagnosis code or medication claim for vali-
dation. The highest PPVs for PsO (85%) and PsO-AC (65%) occurred when a predictive 
algorithm of ≥ 2 MC/PVs was compared to the reference standard of ≥ 1 diagnosis 
code. The majority of PsO-AC false positives had a diagnosis of PsO and pain or joint 
symptoms. NPV and specificity were also high (99 – 100%), while sensitivity was low 
(≤ 30%). Reducing the number of MC/PVs or increasing diagnosis claims decreased 
in type 2 diabetes mellitus. Comprehension of the checklist was assessed based 
on qualitative interviews of each analyst. A measure of the inter-analysts agree-
ment was estimated to ensure the reliability of the checklist. Results: Checklists 
identified from the literature included the checklist developed by the NICE Decision 
Support Unit and the one developed by the ISPOR task force. These two checklists 
were developed for analysts who conduct NMAs as well as analysts who critically 
review NMAs. However, they seem to lack clarity for non-statisticians. We developed 
a new checklist, which included the following items: definition of the study question 
(list of comparators, study population), methods (study selection, data extraction, 
statistical model, selection of fixed versus random effects model, assumptions for 
the base case, heterogeneity and inconsistency assessment and sensitivity analy-
ses), reporting of results (network and source data, median or mean and 95% cred-
ibility interval) and interpretation of results. ConClusions: Our checklist can be 
used by analysts not trained in statistics to prepare or review NMAs to be submitted 
to NICE and/or to populate cost-effectiveness models.
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objeCtives: This work aims to develop a methodology for determining the qualita-
tive composition of an expert group for the purpose of participation in decision-
making in health care technology. Its goal is also to evaluate the methodology 
based on an example of the selection of large medical equipment. Methods: The 
complex weighting factor is a comprehensive evaluation of an expert. It is based 
on the expert’s overall work experience, experience in solving tasks, level of educa-
tion and scientific record, interest in solving the particular task, current position, 
and awareness of how to solve the task. Also taken into account are the relevance 
of the expert’s knowledge and the overall self-evaluation concerning his or her 
total competence in solving the task. For the purpose of validating the method-
ology, 96 potential experts were interviewed. These subjects included managers 
from relevant departments in hospitals and hospital staff members who were from 
72 health facilities in the Czech Republic. Results: Unlike the other models, the 
calculation model that was selected is able to eliminate errors in estimating the 
proportionality of extreme values and to reduce the impact of uncertainty in the 
experts’ overall self-evaluations concerning their total competence to the combined 
ratio. Based on this model, a methodology for selecting experts was developed. A 
statistically significant correlation was found between the complex weighting factor 
and the following characteristics: the expert’s experience in dealing with similar 
tasks (r= 0.512, p< 0.001), the expert’s theoretical background (awareness) and the 
relevance of the expert’s knowledge (r= 0.44, p< 0.001), the expert´s current position 
(r= 0.319, p= 0.002), and the level of his or her education and scientific record (r= 0.28, 
p= 0.007). ConClusions: This methodology will be especially useful in scientific 
and technological forecasting, medical and managerial decision-making, quality 
assessment, and operational research.
PRM210
ModElling longitudinAl tRAjECtoRiES of PAtiEnt-REPoRtEd outCoMES 
to EvAluAtE tREAtMEnt EffECt
Jen M.H.
Eli Lilly and Company, Surrey, UK
objeCtives: To evaluate treatment effect on longitudinal patient-reported out-
comes using appropriate analytical strategy. Methods: This was an ad-hoc analy-
sis of longitudinal patient-reported outcomes using a two stages simulated data 
in which the true model is known, to explore and to evaluate the capability of the 
group-based trajectory method to identify the distinctive features of a highly irregu-
lar but still continuous population distribution of trajectories. Firstly, we created 
six different types of underlying trajectory in which the true model is known and 
added in level-one between occasion random noises. Then we added a level-two, 
between- patients variation (of the random intercept form) with differing variabil-
ity to each of the six distinctive trends. This simulation allows us to examine how 
the software implementation identifies different group trajectories as well as their 
level-one and -two variances. It was recognized that a priori assignment of distinct 
longitudinal trajectories may not be appropriate and that no ability to calibrate 
the precision of individual classifications exists if ex-ante rules are used. Thus, 
latent group-based trajectory model, a method to map the developmental course of 
symptoms and assess heterogeneity in response to clinical interventions, was used 
to identify patient groups with varied response. Results: The fitted trajectories 
closely approximate the true shapes and there is also a close correspondence for the 
percentage of places attributed to each group. Even the size of the level 1 random 
term is correctly estimated. The semi-parametric group-based trajectory method 
has demonstrated unequivocally its capability to capture the unobserved subgroups 
in the presence of considerable level-1 random variation. ConClusions: Patients 
in many disease areas experience changes in QoL in different ways. Identification 
of those groups is essential for appropriate evaluation of therapy treatment effects 
and identification of factors contributing to those groupings.
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objeCtives: Clinical development of therapies for rare diseases can benefit from 
improvements to conventional trial designs. This study evaluated a new trial design, 
the randomized Blind Start. Methods: The Blind Start design randomizes patients 
